The study also revealed that another drug thought to prevent Type 2 diabetes -- ramipril -- has a minimal impact on the disease.
Forbes.com observes that
Still, the results are a scientific win because they show that it is possible to develop drugs that prevent diabetes. An entirely new class of treatments is racing to market in the form of Januvia and Galvus, experimental pills developed by Merck and Novartis, which work in a new way. The FDA is expected to approve or reject Januvia in mid-October and Galvus in November. It's possible that Merck and Novartis could find a way to walk through the door that Glaxo has already opened.